Skip to content

Fighting to Preserve the Benefits of the 340B Program

  • About Us
  • Contact Us
Top Bar Menu
Facebook page opens in new windowTwitter page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
    • Webinars
  • News

thought catalog kkysaOcVE94 unsplash

BMS is the 12th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies; Permits Designation of One Contract Pharmacy for Three Cancer Drugs

Drug Pricing, NewsBy Andrea JeriaJanuary 20, 2022

By email dated January 14, 2022, Bristol Myers Squibb (BMS) announced that, effective March 1, 2022, it will implement a new 340B contract pharmacy policy impacting two drug categories: non-immunomodulatory…

eye g4f3076735 1920

Second Sight Updates 340B ESP Terms of Use

Drug Pricing, NewsBy Andrea JeriaJanuary 6, 2022

In October 2021, Second Sight, the owner of 340B ESP, updated the Terms of Use (TOU) that covered entities must agree to when registering for the 340B ESP platform.  There…

volodymyr hryshchenko m1Hq4ibP9rc unsplash

New AbbVie and Lilly Contract Pharmacy Policies

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaJanuary 6, 2022

AbbVie is the 11th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies By letter dated December 29, 2021, AbbVie announced that, effective February 1, 2022, it will implement…

glsun guilin WNX6uk 1LV4 unsplash

UCB Latest Manufacturer to Announce Restrictive Contract Pharmacy Policy; HRSA Issues Statement Regarding Manufacturer Lawsuits

Drug Pricing, HHS, HRSA, NewsBy Andrea JeriaNovember 23, 2021

By letter dated November 22, 2021, drug manufacturer UCB, Inc. notified covered entities that it is “altering its 340B policy” and will no longer honor contract pharmacy arrangements, effective December…

Eighth Circuit Issues Favorable ERISA Preemption Decision that Likely Protects State 340B Anti-Discrimination Laws

Drug Pricing, News, RulingsBy Andrea JeriaNovember 19, 2021

On November 17, the U.S. Court of Appeals for the Eighth Circuit (Eighth Circuit) issued its decision in Pharmaceutical Care Management Association v. Wehbi, et al., ruling that North Dakota’s…

courthouse g329b35186 1280

Update on 340B Contract Pharmacy Litigation — Decisions Issued in Four Manufacturer Lawsuits

Drug Pricing, HHS, HRSA, News, RulingsBy Andrea JeriaNovember 8, 2021

On Friday, November 5, two federal courts issued decisions in four of the lawsuits that drug manufacturers filed against HHS challenging HHS’ May 17 cease-and-desist letters (“May 17 Letters”) notifying…

RWC 340B Logo hi res

RWC-340B Applauds Court’s “Fairest and Most Reasonable” Interpretation of the 340B Drug Pricing Program: Manufacturer Actions Shall Not Undermine the Safety Net

Drug Pricing, HHS, HRSA, News, RWC-340BBy Andrea JeriaNovember 2, 2021

PRESS STATEMENT: FOR IMMEDIATE RELEASE         Contact: Peggy.Tighe@PowersLaw.com RWC-340B Applauds Court’s “Fairest and Most Reasonable” Interpretation of the 340B Drug Pricing Program:  Manufacturer Actions Shall Not Undermine the Safety Net…

index

Indiana Federal Court Issues Decision in Eli Lilly’s Contract Pharmacy Lawsuit

Drug Pricing, HHS, HRSA, News, Rulings, RWC-340BBy Andrea JeriaNovember 1, 2021

On Friday, the U.S. District Court for the Southern District of Indiana (the Court) issued a decision supporting HRSA’s statutory interpretation, as reflected in HRSA’s May 17 determination, that Eli…

istockphoto 1285497344 612x612 1

Boehringer Ingelheim Is Latest Manufacturer to File a Lawsuit Against HHS On Contract Pharmacy Program

Drug Pricing, HHS, HRSA, RWC-340BBy Andrea JeriaOctober 26, 2021

On October 25, 2021, drug manufacturer Boehringer Ingelheim Pharmaceuticals, Inc. filed a lawsuit in the U.S. District Court for the District of Columbia against HHS, alleging that HHS’s policy on…

hammer ge8ffaccd3 1920

Rep. Matt Rosendale Introduces Legislation: DSH 340B Eligibility Moratorium, Regulations Limiting Such Eligibility, and Increased Reporting Requirements

Congress, Drug Pricing, HRSA, News, RegulationsBy Andrea JeriaOctober 11, 2021

On September 30, U.S. Representative Matt Rosendale (R-MT) introduced the Drug Pricing Transparency and Accountability Act (H.R. 5463), which would amend the 340B statute to add a two-year moratorium on…

→123→
                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset